Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measu...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2020-09-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/26/9/20-1840_article |
| _version_ | 1818335967503712256 |
|---|---|
| author | Hannah Clapham James Hay Isobel Routledge Saki Takahashi Marc Choisy Derek Cummings Bryan Grenfell C. Jessica E. Metcalf Michael Mina Isabel Rodriguez Barraquer Henrik Salje Clarence C. Tam |
| author_facet | Hannah Clapham James Hay Isobel Routledge Saki Takahashi Marc Choisy Derek Cummings Bryan Grenfell C. Jessica E. Metcalf Michael Mina Isabel Rodriguez Barraquer Henrik Salje Clarence C. Tam |
| author_sort | Hannah Clapham |
| collection | DOAJ |
| description | Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2. |
| first_indexed | 2024-12-13T14:31:50Z |
| format | Article |
| id | doaj.art-a84b78f798f04a3da68c933f245e211a |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-13T14:31:50Z |
| publishDate | 2020-09-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-a84b78f798f04a3da68c933f245e211a2022-12-21T23:41:48ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592020-09-012691978198610.3201/eid2609.201840Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and ImmunityHannah ClaphamJames HayIsobel RoutledgeSaki TakahashiMarc ChoisyDerek CummingsBryan GrenfellC. Jessica E. MetcalfMichael MinaIsabel Rodriguez BarraquerHenrik SaljeClarence C. TamSerologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2.https://wwwnc.cdc.gov/eid/article/26/9/20-1840_articleCOVID-19coronavirus diseaseSARS-CoV-2severe acute respiratory syndrome coronavirus 2virusesrespiratory infections |
| spellingShingle | Hannah Clapham James Hay Isobel Routledge Saki Takahashi Marc Choisy Derek Cummings Bryan Grenfell C. Jessica E. Metcalf Michael Mina Isabel Rodriguez Barraquer Henrik Salje Clarence C. Tam Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity Emerging Infectious Diseases COVID-19 coronavirus disease SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 viruses respiratory infections |
| title | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
| title_full | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
| title_fullStr | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
| title_full_unstemmed | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
| title_short | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
| title_sort | seroepidemiologic study designs for determining sars cov 2 transmission and immunity |
| topic | COVID-19 coronavirus disease SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 viruses respiratory infections |
| url | https://wwwnc.cdc.gov/eid/article/26/9/20-1840_article |
| work_keys_str_mv | AT hannahclapham seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT jameshay seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT isobelroutledge seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT sakitakahashi seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT marcchoisy seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT derekcummings seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT bryangrenfell seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT cjessicaemetcalf seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT michaelmina seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT isabelrodriguezbarraquer seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT henriksalje seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT clarencectam seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity |